JD Health (06618) released its audited 2025 annual results, reporting revenue of 73.44 billion RMB, an increase of 26.30% year over year. Gross profit was 18.20 billion RMB, up 36.70%. Operating income reached 3.80 billion RMB, surging 158.50%, while profit for the year grew 29.10% to 5.37 billion RMB.

Non-IFRS measures showed further improvements. Non-IFRS operating income was 4.39 billion RMB, 68.90% higher year over year, and non-IFRS profit stood at 6.53 billion RMB, marking a 36.30% increase. Annual active users reached 217.70 million over the 12 months ended December 31, 2025.

Management highlighted continued efforts in strengthening omnichannel retail pharmacy capabilities, partnering with pharmaceutical companies to introduce over 100 new drugs and expanding AI-driven healthcare services. On-demand retail saw notable progress, with coverage of online medical insurance payment services extending to 29 cities and over 300 self-operated pharmacies in operation as of the period end.

Cash resources totaled 69.50 billion RMB. Research and development expenses rose to 1.63 billion RMB, reflecting increased technology inputs. There were no outstanding borrowings, and no material acquisitions were undertaken during the period. The Board has not recommended a final dividend for 2025.